TY - JOUR
T1 - An open trial of climatotherapy at the dead sea for patch-stage mycosis fungoides
AU - Hodak, Emmilia
AU - Gottlieb, Alice B.
AU - Segal, Tzvi
AU - Maron, Lea
AU - Lotem, Michal
AU - Feinmesser, Meora
AU - David, Michael
N1 - Funding Information:
Supported by the Dead Sea Medical Research Center, the Dead Sea, Israel.
PY - 2004/7
Y1 - 2004/7
N2 - Background Climatotherapy at the Dead Sea (CDS) is a well-established therapeutic modality for moderate to severe psoriasis vulgaris, resulting in sustained remissions. It has also been found to be effective for atopic dermatitis, another T-cell-mediated dermatosis. Objective We sought to prospectively evaluate the efficacy of CDS in patch-stage mycosis fungoides. Methods A total of 12 patients with patch-stage mycosis fungoides (6 with stage IA and 6 with stage IB) were treated with CDS as monotherapy for 28 consecutive days according to the protocol for psoriasis, ie, a gradual increase of sun exposure to a maximum of 3 hours daily. Results A total of 9 patients achieved a complete clinical response (CCR), defined as no disease activity present; 2 achieved an almost CCR, defined as the reduction by more than 90% of disease activity; and 1 achieved a partial response, ie, reduction by more than 50% of disease activity. A CCR was achieved in all the patients with stage IA disease and in 3 of the 6 patients with stage IB disease. Of the 9 with a CCR, 6 also showed histopathologic clearing. Duration of the remissions, during which no therapy was allowed except for emollients, lasted from 2 to 9 months (mean: 5 months). No serious short-term side effects were recorded. Conclusion CDS appears to be an effective, well-tolerated therapy for patch-stage mycosis fungoides.
AB - Background Climatotherapy at the Dead Sea (CDS) is a well-established therapeutic modality for moderate to severe psoriasis vulgaris, resulting in sustained remissions. It has also been found to be effective for atopic dermatitis, another T-cell-mediated dermatosis. Objective We sought to prospectively evaluate the efficacy of CDS in patch-stage mycosis fungoides. Methods A total of 12 patients with patch-stage mycosis fungoides (6 with stage IA and 6 with stage IB) were treated with CDS as monotherapy for 28 consecutive days according to the protocol for psoriasis, ie, a gradual increase of sun exposure to a maximum of 3 hours daily. Results A total of 9 patients achieved a complete clinical response (CCR), defined as no disease activity present; 2 achieved an almost CCR, defined as the reduction by more than 90% of disease activity; and 1 achieved a partial response, ie, reduction by more than 50% of disease activity. A CCR was achieved in all the patients with stage IA disease and in 3 of the 6 patients with stage IB disease. Of the 9 with a CCR, 6 also showed histopathologic clearing. Duration of the remissions, during which no therapy was allowed except for emollients, lasted from 2 to 9 months (mean: 5 months). No serious short-term side effects were recorded. Conclusion CDS appears to be an effective, well-tolerated therapy for patch-stage mycosis fungoides.
UR - http://www.scopus.com/inward/record.url?scp=3042781169&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2003.11.052
DO - 10.1016/j.jaad.2003.11.052
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 15243521
AN - SCOPUS:3042781169
SN - 0190-9622
VL - 51
SP - 33
EP - 38
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 1
ER -